Half-year Results

GlobalData Plc (LSE: DATA, GlobalData, the Group), the leading data, insight, and technology company, today publishes its results for the half year ended 30 June 2026 (HY26).

The period saw stable operational performance alongside the continued strategic evolution of the Group's operating model to an end-market divisional structure to drive long-term value creation.

Commenting on H1 performance and GlobalData's strategic evolution, Mike Danson, Chief Executive Officer of GlobalData Plc, said: "As we approach the conclusion of the Growth Transformation Plan, we can reflect on the significant operational progress made. We have established an end-market-led divisional structure, brought entrepreneurial leadership closer to our customers and created a corporate centre focused on disciplined value creation. While H1 saw substantial organisational progress, revenue and growth remained below our ambitions and the benefits of the transformation have not yet been reflected in our financial performance. The foundations are now in place, and our focus is firmly on execution.

Healthcare provides a clear proof point for the strength of the model and demonstrates its potential to be replicated across the portfolio. We are also seeing encouraging early signs elsewhere: Consumer delivered underlying revenue growth of 7% in the half while renewal rates remained resilient across both the Healthcare and Non-Healthcare divisions.

Our immediate priority is to accelerate underlying revenue growth, supported by targeted investment. Underlying revenue growth has been more muted than expected, and full-year revenue is now expected to track consistent with first-half performance - still in line with market expectations, albeit towards the lower end of the range. This revenue outturn, together with new investment in AI-native workflows, proprietary data and human expertise, means full-year margins are expected to be more consistent with the first half. These investments are designed to improve revenue quality, driving stronger renewal rates, accelerate growth over the longer term, as well as driving margin efficiency.

Our continued investment for growth is focused on building market-leading businesses, while maintaining a flexible and disciplined approach to capital allocation and to realising value across the portfolio. The resilience of our subscription revenues and strength of balance sheet provide the capacity to invest both for growth and return capital to shareholders."

Resilient growth in challenging markets

• Revenue grew 4% to £162.9m (HY25: £156.5m), with underlying¹ growth of 1%, reflecting a challenging macroeconomic backdrop in which sales cycles elongated industry-wide, as well as the ongoing embedding of key investments and transformation across the business.

Underlying profitability in line with HY25

• Adjusted EBITDA¹ increased 5% to £54.8m (HY25: £52.1m) (reflecting flat performance on an underlying basis), with Adjusted EBITDA margin¹ improving one percentage point to 34% (HY25: 33%).
• Adjusted operating profit¹ increased 6% to £46.7m (HY25: £44.0m), with adjusted operating profit margin¹ improving one percentage point to 29% (HY25: 28%).
• Profit before tax reduced by 6% to £23.2m, as finance charges increased due to increased bank debt.
• Adjusted fully diluted EPS¹ increased 8% to 2.7p (HY25: 2.5p).

Customer relationships are holding and forward visibility of FY26 is strong

• Volume and value renewal rates have been consistent through the half across both Healthcare and Non-Healthcare.
• Contracted Forward Revenue¹ grew 4% to £163.3m (HY25: £157.4m), reflecting underlying growth of 1%, providing strong visibility for the remainder of FY26 and beyond.

Active measures being undertaken

• Investment in proprietary data and AI-first transformation underway, which will enhance the depth, coverage and timeliness of our key datasets. These investments are focused on improving KPI's around client usage and renewal rates, with some AI-driven operational efficiencies expected to flow into FY27 and beyond.
• Continue to invest in sales and go-to-market teams

o We have clear examples of where existing investment has worked well in the past 18 months (Consumer division grew underlying 7% in H1), as well as Non-Healthcare Inside Sales (which have started to see signals in churn improvement) and we will continuously evolve and invest in our sales teams, drawing on best practice in the Group.

• Strong central model to drive value via a centralised operating model, allowing our divisional management teams to focus on their customers and end markets.
• Strengthened leadership, deeper talent and playbooks.

Disciplined capital allocation and a clear medium-term path

• The Group continues its flexible strategy on capital allocation, with the acquisition of Cambridge Healthcare in the first half as well as £19m returned to shareholders through share buybacks.
• A further £30m tender was announced at the end of H1, which has now completed, taking capital returned to over £49m during FY26 to date, contributing to 8% increase in Adjusted diluted earnings per share.
• Our medium-term targets reflect a clear focus on accelerating underlying revenue growth. With supporting investment for growth acceleration, we expect a more measured recovery of Adjusted EBITDA margins towards 40%.

Continued M&A value opportunities:

• For Non-Healthcare, the near-term M&A focus is on realising revenue synergy opportunities from recent acquisitions, with M&A in the Non-Healthcare division de-prioritised in the interim as previously signalled.
• The Healthcare division will continue to actively pursue M&A with a focus on assets with revenue growth, proprietary content, quality of earnings and high customer retention metrics.

Highlights

Financial results for the six months ended 30 June 2026.

Outlook: building momentum and evolving strategy to drive long-term value creation

Note 1: Defined in the explanation of non-IFRS measures on page 18.

Note 2: Current analyst consensus for FY26 is as follows: Revenue within a range of £325.3m - £335.7m, Adjusted EBITDA within a range of £121.0m - £126.7m.

One Platform Model

GlobalData's One Platform model is the foundation of our business and is the result of years of continuous investment, targeted acquisitions, and organic development. This model governs everything we do, from how we develop and manage our products, to our approach to sales and customer success, and supporting business operations At its core, this approach integrates our proprietary data, human expertise, and purpose-built AI into an integrated suite of solutions, designed to serve a broad range of industry markets and customer needs on a global basis. The operational leverage this provides means we can respond rapidly to changing customer needs and market opportunities, and continuously manage and develop products quickly, at scale, with limited capital investment as well as providing unique integration opportunities for M&A.

Strategic Priorities

CHIEF EXECUTIVE'S REVIEW

GlobalData today: the gold standard for trusted intelligence

At GlobalData, we build and operate market-leading businesses in information services, driven by a passion for the opportunities that arise from the convergence of data, people, and AI. This is the GlobalData way and our entrepreneurial heritage sets us apart. We are business builders, innovators, and investors - combining the deep sector and market knowledge of a proven operator, with the financial acumen of a successful investor.

We've established a buy and build heritage over a number of years building market leading businesses, creating a truly differentiated intelligence platform that unites the power of proprietary data, human expertise, and AI. Our global scale and diversified platform allow us to operate in almost every sector and market, with a portfolio of market leading businesses with established and defensible positions.

Our culture and expertise is an advantage, built by experienced entrepreneurs and passionate operators who have lived the journey of successfully acquiring, building, and scaling businesses. Our teams are hands-on, proactive to act, and support our portfolio businesses in seizing their biggest opportunities and navigating common challenges. Our scale lets us transfer expertise across domains - spanning strategy, commercial, product, and M&A - across our operations and businesses, creating a dynamic portfolio united in a common purpose.

Our platform-based operating model is powered by a single platform and underpinned by a significant amount of proprietary data - built through years of continuous investment, targeted acquisitions, and organic development - empowers everything from product development to sales and customer success, to operations. It is proven to deliver a tangible advantage to our businesses. This operating leverage lets us rapidly respond to changing customer needs and market opportunities, manage and develop our businesses at scale, with limited capital investment.

Our culture, platform, and portfolio give us financial strength and strategic optionality within our operating model - enabling long-term, shareholder-first investment, whilst remaining flexible to value creation opportunities. The combination of platform capabilities and financial expertise strengthens every deal, capital raise, and partnership, supported by a model that enables us to deploy talent across the portfolio and quickly stand-up world-class teams to support new strategic initiatives, acquisitions and joint ventures.

Philosophy and principles of our strategic evolution to an end-market divisional structure

Our strategic approach is grounded in Customer Obsession, which shapes how we make decisions across sales, products and operations. Our foundations are strong, and the rigour with which we run our business is strengthening further. The progress made since launching the Growth Transformation Plan gives us confidence that the model is working.

Our portfolio is powered by these strong foundations. We have adopted a philosophy of embedding best practice playbooks across the business to ensure consistency and accelerate value creation. This philosophy manifests in our transition to an end-market divisional structure, pairing the GlobalData platform advantage with market-focused businesses led by dedicated management and go-to-market teams. By aligning our organisation around customer needs rather than product lines, we are able to respond more rapidly to changing customer requirements and market opportunities while maintaining the operational leverage of our One Platform model. Our central leadership operationalises our strategic philosophy by creating a mechanism to share, scale and evolve what works across the business.

Our model is built on a structural advantage:

Healthcare is the proof point of the divisional approach

By embedding our solutions-based sales methodology and applying our playbooks for go-to-market and customer engagement, we have demonstrated the effectiveness of the model in a large, complex end market.

The sale of 40% interest in Healthcare during 2024 established a valuation of £1.115bn for the division, equivalent to over 20x EBITDA/ EV multiple. The transaction enhanced the Group's financial flexibility, supporting more than £132m of acquisitions and the return of over £189m to shareholders via tender offers and share buybacks.

Healthcare now has a dedicated management team focused on accelerating growth, supported by the Group's central capabilities and playbooks. This separation demonstrates GlobalData's broader value creation thesis: the ability to identify, isolate, optimise and unlock value in high-potential business segments with decisive speed.

HY26

During the first half, on an underlying basis revenue growth was 1%. The reported revenue growth was 4%, which was impacted by adverse currency headwinds (particularly in the first quarter) and benefitted from M&A based growth from Stylus (part of our Consumer business) and Cambridge Healthcare (Healthcare) as well as a one-off benefit of complimentary period revenue adjustment of £3.3m.

The underlying revenue performance was underpinned by robust renewal rates, both on a volume and value basis (>£20k: Value Renewal Rate 91% (December 2025: 89%), Volume Renewal Rate 83% (December 2025: 83%)).

In order to improve our organic growth rate, we have a significant opportunity if we can reduce churn and increase the volume renewal rates. We have seen some signals of improvement when we look at the performance of our Inside Sales team in Non-Healthcare, who have introduced stronger processes and focus on our smaller clients and we will continuously evolve and invest in our sales teams, drawing on best practice in the Group.

There are some variations in growth around the Group, both Healthcare and Non-Healthcare underlying revenue growth was 1%. Consumer delivered high single digit growth, including 7% underlying growth, and Industrials delivered low-single-digit growth, offset by performances in the rest of the portfolio. We believe the growth rates reflect the different stages of maturity in the management teams in place, but are confident in the teams we now have established across the business in the last 12-18 months.

Underlying Adjusted EBITDA was flat on a like-for-like basis, with reported Adjusted EBITDA increasing by 5% to £54.8m (HY 2025: £52.1m). Adjusted EBITDA margin increased to 34% (HY 2025: 33%). Margin progression was moderated by the effect of recent acquisitions, continued investment in the business and modest underlying revenue growth.

Continued investment in AI-native workflows, proprietary data and our go-to-market teams will support organic revenue opportunities

The focus on long-term shareholder value creation is focused on maximising the Group's organic revenue opportunities over the longer term. We are focused on two Group initiatives to achieve this objective.

• Investment initiative launched to improve customer outcomes with our AI-first transformation programme

During the period, we have launched GlobalData's wide-reaching AI-first internal transformation programme to modernise how the Group builds and delivers proprietary content by orchestrating AI-native workflows with human expertise, accelerating product development, deepening customer engagement and driving the next phase of growth through to 2030.

Our proprietary data is the cornerstone and foundation of this key initiative - our AI-first initiative to sharpen our workflows and processes to deliver deeper, broader and more timely data coverage, all while continuing to build our proprietary data assets. The financial benefit of AI-driven operational efficiencies is expected to begin flowing through during the end of the second half of FY26 and into FY27.

This programme represents a fundamental shift in how we operate, embedding AI into our core content creation and product development processes rather than treating it as an add-on capability. The integration of AI-native workflows with human expertise allows us to maintain the quality and insight that our customers expect while improving our speed and scale of delivery. We expect the implementation to drive operational efficiency in the medium and long-term, but the project is fundamentally focused on improving customer outcomes through broader, deeper and more timely data and insights to our clients. We expect this initiative to be a catalyst both accelerating top-line growth as well as structurally improving margins.

Continued investment in our go-to-market teams

To accelerate growth we will continue to invest in our go-to-market teams. We have clear examples of where existing investment has worked well in the past 18 months (Consumer division grew underlying 7% in H1), as well as Non-Healthcare Inside Sales (which have started to see signals in churn improvement) and therefore we will continuously evolve and invest in our sales teams, drawing on best practice in the Group.

Promotion to FTSE 250

During the period, the Group achieved two further milestones in its growth journey: our move from AIM to the Main Market of the London Stock Exchange, completed on 5 March 2026, and our subsequent promotion to the FTSE 250 on 22 June 2026. Together, these mark a significant step change in GlobalData's profile and stand as further proof points of the momentum behind our strategy.

Capital allocation

A key advantage of GlobalData's business model is the optionality it creates for business building. This is driven by the diversity of assets across the platform, multiple potential combinations between them, a track record of successful acquisitions alongside a pipeline of future opportunities, and varying levels of asset maturity across the Group. This flexibility allows us to respond quickly to market opportunities and, where appropriate, bring assets together to accelerate growth and create additional value.

This optionality informs our approach to capital allocation, allowing the Group to deploy capital flexibly and be opportunistic in how it delivers shareholder value creation. Since 2024, we have invested £132m on acquisitions and returned £189m to shareholders through tender offers and share buybacks, demonstrating our ability to balance investment for growth with direct capital returns.

The Group remains committed to operating within its target net leverage range of 2-3x. We have recently strengthened our financing position by increasing our existing Non-Healthcare facility by £60m to £245m, on a three-year term with a one-year extension option, subject to customary closing conditions. We have also extended the £200m Healthcare facility by a further year to December 2028. Together, these actions provide the Group with enhanced flexibility and capacity to support its capital allocation priorities.

Outlook

The focus on long-term shareholder value creation is focused on maximising the Group's organic revenue opportunities over the longer term.

Leadership, talent and thank you to employees

The first half of 2026 has provided further validation of our operational model and the transformation undertaken over the past three years. While the financial benefits are not yet reflected in our results, due in part to the different stages of maturity across our businesses, we now believe we have the operating model and talent needed to accelerate organic revenue growth. This transformation has demanded considerable effort from teams across the Group. This deliberate, above-market investment in senior and mid-tier leadership over the last two years has been made to ensure we have a competitive advantage built not just on technology, but on the people who design, deploy, and continuously improve it.

Our strong talent base of analysts, researchers, technologists, data scientists and AI specialists are embedded across the business, working hard to give our global clients the data they need to make informed decisions quickly. This deep pool of talent and expertise has taken years to assemble. It underpins the resilience of our platform and strengthens our ability to innovate and succeed in an AI-first environment.

I would like to thank our people for their commitment and adaptability as we have embedded new ways of working and repositioned the business for long-term value creation. Our four strategic priorities - Customer Obsession, World-Class Product, Sales Excellence and Operational Agility - continue to guide how we work together and the standards we hold ourselves to.

Mike Danson

Chief Executive Officer

FINANCIAL REVIEW

ADJUSTED FIGURES

1 Defined in the explanation of non-IFRS measures on page 18.

2 In prior years, the Group included share-based payments and associated costs, as well as unrealised foreign exchange costs/(gains) as an adjustment to operating profit. The Group updated the classification of adjusting items within the adjusted profits calculation in 2025 with a view to provide more comparable performance metrics across its peers. As a result of the amended calculation method, prior year comparatives have been amended to report adjusted profits on a consistent basis.

Reconciliation of statutory numbers to alternative performance measures:

1 Defined in the explanation of non-IFRS measures on page 18.

The financial position and performance of the business are reflective of the core financial elements of our business model: visible and recurring revenues, high incremental margins, scalable opportunity and strong cash flows.

The Directors believe that Adjusted EBITDA, Adjusted EBITDA margin, Adjusted profit before tax, Adjusted profit after tax and Adjusted earnings per share provide additional useful information on the operational performance of the Group to shareholders (as well as understanding the underlying performance of these measures), and internally we review the results of the Group using these measures. The term 'Adjusted' is not a defined term under IFRS and may not therefore be comparable with similarly titled profit measures reported by other companies. It is not intended to be a substitute for, or superior to, IFRS measures of profit.

Executive Summary

Underlying revenue grew 1%, with currency headwinds (especially in Q1) offset by M&A growth from Stylus and Cambridge Healthcare. Renewal rates stayed robust (Value 91%, up from 89% at the end of December 2025; Volume 83%, flat compared with the end of December 2025), but lifting volume renewal rates and cutting churn remains our biggest lever for organic growth, and early signs from Non-Healthcare Inside Sales, with tighter processes and sharper focus on smaller clients, are encouraging.

Adjusted EBITDA rose 5% to £54.8m, though underlying growth was flat (Adjusted EBITDA margin of 34%, up from 33%) as was held back by M&A dilution and continued investment against low single-digit underlying revenue growth.

Revenue

Revenue grew by 4% in the six months to June 2026; this was driven mainly by recent acquisitions (Stylus and Cambridge Healthcare), which contributed £7.9m of year-on-year growth (5%), complimentary period revenue adjustment of £3.3m1, alongside underlying revenue growth of 1%. These were somewhat offset by adverse foreign currency movements of £3.4m (2%). Total revenue for the half was £162.9m (HY 2025: £156.5m).

Subscription revenue (representing 76% of revenue, HY 2025: 74%) grew by 6%. The volume and value renewal rates (measured over the last twelve months) have remained consistent at 83% and 91% respectively for clients spending more than £20,000 (December 2025 Volume Renewal Rate 83%, December 2025 Value Renewal Rate 89%).

Other, non-subscription revenue, declined by 2%, which is reflective of discontinued and disposed non-core assets not contributing to revenue in HY26.

The table below is included to reconcile the reported revenue and the impact of acquisitions, currency movements and other items to show the underlying revenue performance in the period.

£m

1 Revenue associated with complimentary periods which has been aligned with the provisions of IFRS15 'Revenue from Contracts with Customers'. This had a catch-up effect in HY 2026 but relates to revenue earned in previous years.

2 Events rephased as a result of disruption in the Middle East.

3 The Group disposed of Internet Business Group Limited on 31 October 2025. Discontinued non-core publications and events included in HY 2025 revenue.

Profit before tax

Profit before tax for the period declined by £1.5m to £23.2m (HY 2025: £24.7m) reflecting an increase in operating profit offset with increases to finance charges driven by higher bank debt.

Adjusted EBITDA

Adjusted EBITDA increased by 5% to £54.8m (HY 2025: £52.1m). Revenue growth of £6.4m was offset with cost increases of £3.7m, meaning that the overall net increase to Adjusted EBITDA was £2.7m. Adjusted EBITDA margin increased to 34% (HY 2025: 33%). Included within Adjusted EBITDA for HY 2026 is £3.3m of revenue associated with complimentary periods which has been aligned with the provisions of IFRS15 'Revenue from Contracts with Customers'. This has had a one-off beneficial impact in HY 2026.

£m

Adjusting items

Adjusting items (detailed in note 7) totalled £18.1m during the period (HY 2025: £19.0m). Significant items include:

Finance costs

Net finance costs have increased by £3.9m to £7.7m (HY 2025: £3.8m), including IFRS16 leases interest cost of £0.6m (HY 2025: £0.6m). The increase is as a result of increased average drawn debt in the period of H1 2026 compared with H1 2025. The cash paid in interest in HY 2026 was £6.5m (HY 2025: £3.2m).

Leases

Within our operating costs, depreciation in relation to right-of-use assets was £2.4m (HY 2025: £2.4m). Our net finance costs include interest of £0.6m in relation to lease liabilities (HY 2025: £0.6m).

Foreign exchange impact on results

The Group derives around 60% of revenues in currencies other than Sterling, compared with around 40% of its cost base. The impact of currency movements in the period reduced revenue by £3.4m.

1 Operating costs excluding adjusting items.

2 Defined in the explanation of non-IFRS measures on page 18.

Taxation

The interim period income tax expense has been calculated using the forecast effective tax rate that would be applicable to expected total annual earnings, i.e. the estimated average annual effective income tax rate applied to the pre-tax income of the interim period. To the extent practicable, where different income tax rates apply to different categories of income, a separate rate has been used for each individual category of interim period pre-tax income.

Using this approach, the overall annual effective income tax rate is currently forecast to be 28.4% (HY 2025: 31.8%). This broadly represents the blended corporation tax rate for FY 2025 in the UK of 25.0%, adjusted for expenses which are not deductible for tax purposes (1.2%), including M&A and restructuring costs incurred to facilitate the Company's strategic agenda, an increase in un-recognised deferred tax assets (1.9%) plus other net permanent difference (0.3%).

Reconciliation of statutory income tax charge to adjusted income tax charge is presented below:

The adjusted tax charge for HY 2025 has been restated due to the calculation of adjusted profits being amended during the financial year ended 31 December 2025, which has been further discussed within the earnings per share section of this report.

Earnings per share

1 Defined in the explanation of non-IFRS measures on page 18.

In prior years, the Group included share-based payments and associated costs, as well as unrealised foreign exchange costs/(gains) as an adjustment to operating profit. The Group updated the classification of adjusting items in 2025 with a view to provide more comparable performance metrics across its peers. As a result of the amended calculation method, prior year comparatives have been amended to report adjusted profits on a consistent basis.

Basic EPS was 1.2 pence per share (HY 2025: 0.8 pence per share). Fully diluted profit per share was 1.2 pence per share (HY 2025: 0.8 pence per share). Adjusted basic earnings per share grew from 2.5 pence per share (restated) to 2.7 pence per share, representing 8% growth.

Share count

Reconciliation of basic number of shares to the diluted number of shares as at the balance sheet date of 30 June 2026:

Dividends

We are pleased to declare an interim dividend of 0.3 pence per share (HY 2025: 0.3 pence). The interim dividend will be paid on 23 October 2026 to shareholders on the register at the close of business on 25 September 2026. The ex-dividend date will be on 24 September 2026.

Cash generation

1 Cash cost relating to contingent consideration included in the Consolidated Statement of Cash Flows within operating activities (£0.8m (HY 2025: £0.3m)) and investing activities (£1.5m (HY 2025: £nil)).

2 Defined in the explanation of non-IFRS measures on page 18.

3 Free cash flow conversion for 2025 has been restated due to the calculation of adjusted profits being amended during the financial year ended 31 December 2025, which has been further discussed within the earnings per share section of this report.

Cash generated from operations reduced by 23% to £50.8m (HY 2025: £66.1m), representing 93% of Adjusted EBITDA (HY 2025: 127%). The reduction of operating cash flow is reflective of £3.4m in cash-settled share based payments paid in HY26 as a one-off transaction, cash collection on three key contracts rephased into H2 2026 (received in H1 during 2025) of £3.2m, adverse impact of foreign exchange on USD collections of £3.0m, and cash held as at 30 June 2025 (and included within operating cash flow HY 2025) of £5.2m in taxes owed on share sales by the employee benefit trust in relation to the exercise of LTIP awards (subsequently remitted in July 2025). On a like-for-like basis, operating cash flow is broadly flat.

Capital expenditure was £3.9m during the period (HY 2025: £3.9m). Capital expenditure represented 2.4% of revenue (HY 2025: 2.5%).

Free cash flow decreased by 27% to £31.3m, reflecting trading movements discussed above. Free Cash Flow represented 80% of Adjusted Profit Before Tax (HY 2025 (restated): 106%).

Reconciliation of net bank debt

The Group defines net bank debt as short- and long-term borrowings less cash and cash equivalents. The amount excludes items related to leases.

1 Cash cost relating to contingent consideration included in the Consolidated Statement of Cash Flows within operating activities (£0.8m (HY 2025: £0.3m)) and investing activities (£1.5m (HY 2025: £nil)).

2 Cash cost relating to acquisitions included in the Consolidated Statement of Cash Flows within investing activities (£20.6m, excluding contingent consideration cash cost (HY 2025: £8.2m)) and financing activities (£1.1m (HY 2025: £nil)).

3 Reflects 12 month rolling Adjusted EBITDA results. £112.9m reconciles as H2 2025 (£58.1m) and H1 2026 (£54.8m), £111.1m reconciles as H2 2024 (£59.0m) and H1 2025 (£52.1m).

M&A transactions

On 1 April 2026, the Group acquired the entire share capital of Cambridge Healthcare Research Limited and its non-trading wholly owned subsidiary for cash consideration of £21.3m plus issuance of a loan note of £0.7m which has been classified as an amount owed to related parties within the Consolidated Statement of Financial Position. Cambridge Healthcare Research is a market-leading competitive intelligence (CI) solutions provider focused on the global life sciences sector. The acquisition creates the opportunity for the Group to build deeper, more embedded relationships with major brands within the pharmaceutical sector and creates the potential for GlobalData to deliver more value to our clients.

Contracted Forward Revenue

Contracted Forward Revenue grew from £157.4m as at 30 June 2025 to £163.3m as at 30 June 2026. Contracted Forward Revenue is a major component of our significant revenue visibility for the forthcoming period.

Mike Danson

Chief Executive

Independent review report to GlobalData Plc

Conclusion

We have been engaged by the company to review the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2026 which comprises the consolidated income statement, the consolidated statement of comprehensive income, the consolidated statement of financial position, the consolidated statement of changes in equity, the consolidated statement of cash flows and related notes 1 to 15.

Basis for Conclusion

Conclusion Relating to Going Concern

Responsibilities of the directors

Auditor's Responsibilities for the review of the financial information

Use of our report

Deloitte LLP

Statutory Auditor

Leeds, United Kingdom

Consolidated Income Statement

Earnings per share attributable to equity holders of the parent:

The accompanying notes form an integral part of this financial report.

Consolidated Statement of Comprehensive Income

Other comprehensive income

Items that will be classified subsequently to profit or loss when specific conditions are met:

The accompanying notes form an integral part of this financial report.

Consolidated Statement of Financial Position

The accompanying notes form an integral part of this financial report.

Consolidated Statement of Changes in Equity

The accompanying notes form an integral part of this financial report.

Consolidated Statement of Cash Flows

The accompanying notes form an integral part of this financial report.

Notes to the Interim Financial Statements

General information

Nature of operations

The principal activity of GlobalData Plc and its subsidiaries (together 'the Group'), is to provide an intelligence and productivity platform that empowers leaders to act decisively in a world of complexity and change. By uniting proprietary data, human expertise, and purpose-built AI into a single, connected platform, we help organisations to see what's coming, move faster, and lead with confidence.

GlobalData Plc ('the Company') is a company incorporated in the United Kingdom (England & Wales) and trades on the main market for listed securities ("Main Market") of London Stock Exchange plc, therefore is publicly owned and limited by shares. The registered office of the Company is John Carpenter House, John Carpenter Street, London, EC4Y 0AN. The registered number of the Company is 03925319.

Basis of preparation

These interim financial statements are for the six months ended 30 June 2026. They have been prepared in accordance with United Kingdom adopted International Accounting Standard 34, "Interim Financial Reporting". They do not include all of the information required for full annual financial statements and should be read in conjunction with GlobalData Plc's audited financial statements for the year ended 31 December 2025.

The financial information for the year ended 31 December 2025 set out in this interim report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the year ended 31 December 2025 have been filed with the Registrar of Companies and can be found on the Group's website www.globaldata.com. The independent auditors' report on the full financial statements for the year ended 31 December 2025 was unqualified and did not contain an emphasis of matter paragraph or any statement under section 498 of the Companies Act 2006.

These interim financial statements have been prepared on the historical cost basis, except for derivative financial instruments, which are measured at fair value.

The interim financial statements are presented in Pounds Sterling (£), which is also the functional currency of the Company. These interim financial statements have been approved for issue by the Board of Directors.

Critical accounting estimates and judgements

In the application of the Group's accounting policies, which are described in the Annual Report and Accounts, the Group is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The same accounting policies and methods of computation are followed in the Consolidated Financial Statements for the six months ended 30 June 2026 as compared with the most recent Annual Report and Accounts. There are no critical accounting judgements or key sources of estimation uncertainty relating to climate-related risks.

Critical accounting judgements

As at 31 December 2025, Management identified a critical accounting judgement in relation to identification of cash-generating units. As at 30 June 2026, Management's assessment of this judgement remains unchanged from that which was disclosed in the most recent Annual Report and Accounts.

Key sources of estimation uncertainty

Management have assessed that there are no key sources of estimation uncertainty as at 30 June 2026.

Principal and emerging risks and uncertainties

The Directors consider that the principal and emerging risks and uncertainties facing the Group as at 30 June 2026, and looking forwards into H2 2026, are consistent with those reported within the Strategic Report of the annual financial statements for the year ended 31 December 2025. The key risks identified were as follows:

Climate change remains an emerging risk for the Group and one that the Board continues to monitor closely. However, as a data and analytics company in which our products are created and distributed digitally, our carbon footprint is considerably smaller than those of many other companies of our size. Therefore, we have concluded that climate change (including existing and emerging regulatory requirements related to climate change) does not represent a principal risk to our business.

Going concern

The Group meets its day-to-day working capital requirements through free cash flow. The Group has closing cash of £48.0m as at 30 June 2026 and net bank debt of £133.0m (31 December 2025: net bank debt of £114.2m), being cash and cash equivalents less short and long-term borrowings, excluding lease liabilities. During December 2024, the Group secured debt financing facilities which would mature in December 2027 (with an option to extend further by a year). The facilities comprised of a £200.0m facility for the Healthcare business ('Healthcare facility') and a separate £185.0m facility for the rest of the Group ('Non-Healthcare facility'). As at 30 June 2026, the Group had drawn £37.0m from the Healthcare facility and £146.0m from the Non-Healthcare facility. During July 2026, the Group secured further financing headroom, upsizing its Non-Healthcare facility by £60.0m to £245.0m (on a new three-year term ending in July 2029 with one year extension option) as well as extending the £200.0m Healthcare facility by a further year to December 2028. The Group drew down £30.0m from the Non-Healthcare facility during July 2026.

The finance facilities were issued with debt covenants which are measured on a quarterly basis. There have been no breaches of covenants in the period ended 30 June 2026. Management has reviewed forecast cash flows and there is no indication that there will be any breach in the next 12 months.

The Directors have a reasonable expectation that there are no material uncertainties that cast significant doubt about the Group's ability to continue in operation and meet its liabilities as they fall due for the foreseeable future, being a period of at least 12 months from the date of approval of the interim financial statements. To complete the going concern assessment the Directors have modelled a base case for each of the two Group segments through to December 2027 (aligned with the two separate facilities) and applied sensitivities to model a reasonable worst-case scenario for each, considering the mitigations available should the future financial performance of the business reflect the reasonable worse-case scenario. The base case models assume that the Group's financial performance is consistent with the full year forecast for 2026 followed by future year growth rates based on Management's expectation of future performance. Under the two base case models, the Group maintains a significant level of positive liquidity headroom. The Directors have applied reasonable downside sensitivities to each base case model, acknowledging that such risks and uncertainties exist. The downside scenarios modelled included the following assumptions:

The Group maintains liquidity and there remains headroom on the covenants during the period running to December 2027 under each scenario modelled across the two segments. The available mitigations identified provided further liquidity and improved covenant headroom to those within the downside scenario models.

Although the statement of financial position shows net current liabilities (current assets less current liabilities), included in current liabilities is £122.7m of deferred revenue that represents future income earnings. Excluding deferred revenue held within current liabilities, the Group has net current assets of £97.2m (31 December 2025: £98.6m).

The Directors therefore consider the strong balance sheet, with good cash reserves and working capital along with financing arrangements, provides ample liquidity. Accordingly, the Directors have prepared the Interim results on a going concern basis.

Accounting policies

This interim report has been prepared based on the accounting policies detailed in the Group's financial statements for the year ended 31 December 2025, which have been applied consistently. The annual financial statements of the Group are prepared in accordance with United Kingdom adopted international accounting standards. The financial statements also comply with International Financial Reporting Standards (IFRSs) as issued by the IASB.

Presentation of non-statutory alternative performance measures

The Directors believe that Adjusted EBITDA, Adjusted EBITDA margin, Adjusted operating profit, Adjusted operating profit margin, Adjusted profit before tax, Adjusted profit after tax and Adjusted earnings per share provide additional useful information on the operational performance of the Group to shareholders, and we review the results of the Group using these measures internally. The term 'adjusted' is not a defined term under IFRS and may not therefore be comparable with similarly titled profit measures reported by other companies. It is not intended to be a substitute for, or superior to, IFRS measures of profit.

Adjustments are made to Adjusted EBITDA and Adjusted operating profits in respect of:

Adjustments are additionally made to Adjusted EBITDA in respect of:

Unrealised operating foreign exchange gain/loss

Taxation

Income tax on the profit or loss for the period comprises current and deferred tax.

Current tax is the expected tax payable on the taxable income for the period, using rates enacted or substantively enacted at the reporting date, and any quantifiable adjustments to the tax payable in respect of previous years.

Deferred taxation is provided in full on temporary differences between the carrying amount of the assets and liabilities in the financial statements and the tax base. Deferred tax assets are recognised only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilised. Deferred tax is determined using the tax rates that have been enacted or substantively enacted by the reporting date and are expected to apply when the deferred tax liability is settled or the deferred tax asset is realised.

Tax is recognised in the income statement for interim reporting purposes using the tax rate that would be applicable to expected total annual earnings, being the estimated average annual effective income tax rate applied to the pre-tax income of the interim period. To the extent practicable, a separate estimated average annual effective income tax rate is determined for each tax jurisdiction and applied individually to the interim period pre-tax income of each jurisdiction. Similarly, if different income tax rates apply to different categories of income (such as capital gains), to the extent practicable, a separate rate is applied to each individual category of interim period pre-tax income.

A standard rate of corporation tax is applied in each jurisdiction to interim items affecting net income that are unusual because of their nature, size or incidence.

The major components of income tax expense in the interim consolidated income statement are:

Segment analysis

The principal activity of GlobalData Plc and its subsidiaries (together 'the Group'), a data, insight, and technology group, is to provide decision-makers across the world's most successful companies with the intelligence to act with conviction. Our connected platform uniquely integrates proprietary data, expert insight, and purpose-built AI into a unified operating system that powers the next generation of intelligence solutions.

The fundamental principle of the GlobalData business model is to provide our clients with subscription access to our proprietary data, analytics, and insights platform, with the offering of ancillary services such as consulting, single copy reports and events. The Group's two reportable segments are 'Data, Analytics and Insights: Non-Healthcare' and 'Data, Analytics and Insights: Healthcare'. The results of the two segments are reported to the Group Chief Executive on a monthly basis.

There is no difference between the Group's operating segments and the Group's reportable segments.

Each segment generates revenue from services provided over a period of time such as recurring subscriptions and other services which are deliverable at a point in time such as reports, events and custom research. The services differ by subject matter which have been grouped into the categories of: Non-Healthcare and Healthcare. There is no material trade between segments.

The Group profit or loss along with Adjusted EBITDA by segment is reported to the Chief Executive on a monthly basis, the Chief Executive also monitors revenue within the operating segments.

The Group considers the use of two operating segments to be appropriate due to:

• Each segment engages in business activities from which it earns revenues and incurs expenses; and
• Discrete financial information is available for each segment.

Each operating segment is assessed by the Board on an Adjusted EBITDA basis. Reportable segment Adjusted EBITDA is used to measure performance as management believes that such information is most relevant in evaluating the results of the reportable segments.

A reconciliation of revenue to Profit after Tax on a reportable segment basis is set out below:

Segment assets and liabilities

Segment assets and liabilities are reported to the CODM in accordance with the management approach defined in IFRS 8: Operating Segments. The Group identifies its reportable segments as Data, Analytics & Insights: Non-Healthcare and Data Analytics & Insights: Healthcare. For balance sheet review, the CODM monitors Data, Analytics & Insights: Healthcare by reviewing the total assets and liabilities held within the separately carved out Healthcare legal entities. All other assets and liabilities held by the Group, including the Data, Analytics & Insights: Non-Healthcare segment, are reported within the 'Remaining Group'. A summary is presented below which reconciles to the Consolidated Statement of Financial Position. Measurements are consistent with the Group's accounting policies. Comparative information has been provided below.

* Certain balances reported to the CODM have been reclassified to conform with the presentation in the Consolidated Statement of Financial Position.

* Certain balances reported to the CODM have been reclassified to conform with the presentation in the Consolidated Statement of Financial Position.

Revenue

As subscriptions are typically for periods of 12 months the majority of deferred revenue held at the balance sheet date will be recognised in the income statement in the following 12 months. As at 30 June 2026, £3.0m (31 December 2025: £1.4m) of the deferred revenue balance will be recognised beyond the next 12 months and therefore has been presented within non-current liabilities within the consolidated statement of financial position.

Geographical analysis

From continuing operations

• Middle East & North Africa
• Operating profit

Operating profit is stated after the following expenses relating to continuing operations:

Earnings per share attributable to equity holders from continuing operations:

Basic

The diluted earnings per share calculation does not include performance-related share options where the performance criteria had not been met in the period, in accordance with IAS 33. The table below shows the number of share options which could become dilutive should future performance criteria be met.

*AUC: Assets under construction which will be transferred to software post development.

Impairment and review of useful lives

During the period, an indicator of impairment was identified regarding customer relationship assets acquired through business combinations, driven by lower renewal rates than originally forecasted at the acquisition dates. In accordance with IAS 36 'Impairment of Assets', Management performed a targeted impairment test on customer relationship assets.

Consequently, an impairment charge of £3.0 million was recognised to reduce the carrying value of these specific assets to their recoverable amount. The remaining useful economic lives of these specific customer relationship assets have also been shortened based on the current renewal rates.

No other impairment indicators were identified on other intangible assets and goodwill allocated to CGUs. Hence, their carrying values remain fully supported.

Borrowings and lease liabilities

Revolving Capital Facility ('RCF') and Acquisition and Capex Facility ('ACF')

During July 2026, the Group secured further financing headroom, upsizing its Non-Healthcare facility by £60.0m to £245.0m (on a new three-year term with 1 year extension option) as well as extending the £200.0m Healthcare facility by a further year to December 2028. As part of the amendments, within both facilities, the ACF element has been transferred into RCF facilities. The Group drew down £30.0m from the Non-Healthcare facility during July 2026.

As of July 2026, the revised loan facilities can be summarised as follows:

Lease payments not recognised as a liability

The Group has elected not to recognise a lease liability for short term leases (leases with an expected term of 12 months or less) or for leases of low value assets. Payments made under such leases are expensed on a straight-line basis. In addition, certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred. The expense relating to payments not included in the measurement of a lease liability is £0.7m for the period ended 30 June 2026 (HY 2025: £0.2m).

The changes in the Group's borrowings can be classified as follows:

Share Purchases

During the period ended 30 June 2026, the Group's Employee Benefit Trust purchased an aggregate amount of nil shares (which represents 0.0% of the total share capital), each with a nominal value of £0.0001 per share, at a total market value of £nil. The purchased shares will be held for the purpose of satisfying the exercise of share options under the Company's Employee Share Option Plan.

During the period ended 30 June 2026, a total of 320,000 shares (which represents 0.0% of the total share capital), each with a nominal value of £0.0001 per share, which were held by the Group's Employee Benefit Trust, were utilised as a result of the vesting of share options. The weighted average price of the exercised options at the date of vesting was £1.84 per share.

The maximum number of shares held by the Employee Benefit Trust (at any time during the period ended 30 June 2026) was 50,779,215 (representing 6.8% of the total share capital).

The purchase of shares by the trust is to limit the eventual dilution to existing shareholders. As at 30 June 2026, the trust holds sufficient shares in respect of all share options currently in issue.

*The remaining share options in Scheme 1 can be exercised anytime until August 2033 and therefore for the purposes of this analysis we have assumed they will be exercised during the second half of 2026.

Share Purchases for Cancellation

The Group has continued its share purchases for cancellation programmes during the period. The purpose of the share buyback programmes is to return surplus capital to shareholders and reduce the Group's share capital. As such, all ordinary shares repurchased by the Group under the share buyback programmes were cancelled.

Total purchases and cancellations during the period ended 30 June 2026 were £18.6m (HY 2025: £39.7m).

Capital management

The Group's capital management objectives are:

• To ensure the Group's ability to continue as a going concern; and

The capital structure of the Group typically consists of net bank debt, which includes borrowings (note 11) and cash and cash equivalents, and equity.

Dividends

The final dividend for 2025 was 1.2 pence per ordinary share and was paid on 1 May 2026. The Board has announced an interim dividend of 0.3 pence per ordinary share. The interim dividend will be paid on 23 October 2026 to shareholders on the register at the close of business on 25 September 2026. The ex-dividend date will be on 24 September 2026.

Treasury reserve

Other reserve

Other reserve consists of a reserve created upon the reverse acquisition of TMN Group Plc in 2009.

Non-controlling interest

The put option in relation to the sale of 40% of the Group's Healthcare business was exercised on 4 June 2024. At this point the sale had been committed to, and legal completion followed shortly afterwards on 28 June 2024, with the Group receiving gross cash proceeds of £451.4m, of which £8.0m was recognised as a related party loan due to Monument Bidco Limited (an Inflexion investment company) at the point of completion which was capitalised during December 2024. As a result of this sale, in line with the provisions of IFRS10: Consolidated Financial Statements, the Group recognised non-controlling interest (NCI) within equity which represents 40% of the Healthcare business sub-group's statement of financial position as at the date of recognition of NCI which was determined as 4 June 2024, being the date the put option was exercised.

Since initial recognition of NCI on 4 June 2024, the following has been allocated to NCI:

• 40% of the Healthcare business sub-group's profit after tax;
• 40% of the movement on the Healthcare sub-group's share-based payment reserve; and
• 40% of the movement on the Healthcare sub-group's foreign currency translation reserve.

During June 2025, a completion accounts adjustment totalling £19.6m was recognised in respect of the sale of GD UK Healthcare Limited (and its subsidiaries) from GlobalData Plc to Washington Bidco Limited, resulting in an adjustment to NCI and Group retained profits of £7.8m.

Summarised financial information in respect of the Group's non-controlling interest is set out below, as at 30 June 2026 the non-controlling interest represents 40% non-controlling interest in the Group's Healthcare business:

Foreign currency translation reserve

Share-based payments

Scheme 1

The Group created a share option scheme during the year ended 31 December 2010 and granted the first options under the scheme on 1 January 2011 to certain senior employees. Each option granted converts to one ordinary share on exercise. A participant may exercise their options (subject to employment conditions) at any time during a prescribed period from the vesting date to the date the option lapses. For these options to be exercised the Group's earnings before interest, taxation, depreciation and amortisation, as adjusted by the Remuneration Committee for significant or one-off occurrences, needed to exceed certain targets. The final financial target for the colleague share option scheme (scheme 1) was met with the 2021 results. During the years ended 31 December 2022 to 31 December 2025, the majority of participants chose to exercise their options, with 0.7m options being deferred as at 31 December 2025, as allowable under the scheme rules. During the period ended 30 June 2026, there were no exercises of deferred options. The remaining 0.7m options can be exercised by participants at any point before August 2033, subject to compliance with the Company's Share Dealing Code. LTIP Scheme 1 is now closed.

Scheme 2

In October 2019 the Group created and announced a new share option scheme and granted the first options under the scheme on 31 October 2019 to certain senior employees. Each option granted converts to one ordinary share on exercise. A participant may exercise their options subject to employment conditions and performance targets being met. For these options to vest the Group's earnings before interest, taxation, depreciation and amortisation, as adjusted by the Remuneration Committee for significant or one-off occurrences, needs to exceed certain targets between 2023 to 2028. The EBITDA target for 2025 was not met, therefore no options vested within this scheme during the period ended 30 June 2026.

Scheme 4

In October 2021 the Group created the 2021 share option scheme (scheme 4). Scheme 4 is targeted at management and senior colleagues below the Executive Management Committee level. The EBITDA targets for Scheme 4 are aligned to Scheme 2, however different proportions of granted options will vest once each target is reached. As noted above, the EBITDA target for 2025 was not met, therefore only a small number of options which were not linked to set targets vested during the period ended 30 June 2026, totalling 0.3m.

The total charge recognised for these schemes during the six months to 30 June 2026 was £0.5m (30 June 2025: £6.8m). The £0.5m charge for the period is a net of (i) a credit of £0.3m in relation to revaluation to fair value of options which currently have no set vesting target and (ii) a charge of £0.8m incurred on payout of the exceptional STIP awards disclosed in the Annual Report and Accounts for the year ended 31 December 2025. No charge has been accrued within the current period in relation to the future targets of Schemes 2 and 4 as it is Management's judgement that the targets are unlikely to be met. The awards of the schemes are settled with ordinary shares of the Company.

Related party transactions

The Board has put in place an additional control framework to ensure related party transactions are well controlled and managed. Related party transactions are overseen by the Audit and Risk Committee which:

o Oversees all related party transactions;

o Ensures transactions are in the best interests of GlobalData and its wider stakeholders; and

o Ensures all transactions are recorded and disclosed on an arm's length basis.

The Group has taken advantage of the exemptions contained within IAS24: Related Party Disclosures from the requirement to disclose transactions between wholly owned Group companies as these have been eliminated on consolidation.

Related Party Transactions: Ultimate Controlling Party

Mike Danson, GlobalData's Chief Executive, owned 60.8% of the Company's ordinary shares as at 30 June 2026 and 61.4% as at 14 September 2026 and is therefore the Company's ultimate controlling party. Mike Danson owns a number of other businesses, a small number of which interact with GlobalData Plc.

During the six months to 30 June 2026, the following related party transactions were entered into by the Group:

Corporate support services

During the period ended 30 June 2026 net corporate support charges of £0.01m were charged to NS Media Group Limited ("NSMGL") and net corporate support charges of £0.03m were charged to Estel Property Investments No.3 Limited ("Estel"), both companies are related parties by virtue of common ownership (HY 2025: £0.01m charge from NSMGL and £0.04m charge to Estel). In both 2026 and 2025 the corporate support charges primarily consisted of a share of the India management team cost and recharged salary costs.

Business Trade Media International Limited ('BTMI')

The Group completed the acquisition of BTMI on 30 August 2024, which was a related party (by virtue of being indirectly owned by Mike Danson). During the period ended 30 June 2026, total recharges from NSMGL in relation to BTMI were £0.04m (HY 2025: £0.1m).

Sales distribution

NSMGL acted as a sales distributor for some GlobalData products. On these transactions they charged agent fees of £0.001m during the period ended 30 June 2026 (HY 2025: £0.03m).

Balances Outstanding

As at 30 June 2026, the total balance receivable from NSMGL was £nil (31 December 2025: £0.007m) and the total balance receivable from Estel was £0.03m (31 December 2025: £nil). There is no specific credit loss provision in place in relation to this receivable and the total expense recognised during the period in respect of bad or doubtful debts was £nil.

Related Party Transactions: Directors and Key Management Personnel

Investment in SIA - Strategy In Action Limited

On 4 June 2024, the Group made an investment of 16.95% in the ordinary share capital of SIA - Strategy in Action Limited ("SiA") for cash consideration of £4.0m. As a result of ordinary share issues made by the company since June 2024, the Group's shareholding as at 30 June 2026 was 16.29%. The Group has representation on the Board and Julien Decot is a common Non-Executive Director across both the Group and SiA. Management assessed that the Group exercises significant influence over SiA, therefore the investment is accounted for using the equity method. The carrying amount of the investment has been adjusted for the Group's share of the post-acquisition profits or losses of SiA (totalling £0.1m loss for the period ended 30 June 2026 (HY 2025: £0.1m profit), which has been recognised in the Group's profit or loss) plus the Group's share of the post-acquisition change in other comprehensive income of SiA (totalling £nil for the period ended 30 June 2026 (HY 2025: £nil), which has been recognised within other comprehensive income of the Group). In addition, the Group has recognised the impact of dilution of shareholding within profit or loss during the period, totalling a loss of £0.2m for the period ended 30 June 2026 (HY 2025: £nil). As a result of the shareholding, the Group is exposed to financial risks including potential funding requirements and exposure to potential future losses; however given the size of the shareholding these risks are not deemed significant to the Group.

Directors and Key Management Personnel Remuneration

Balances Outstanding

There were no balances outstanding in relation to Directors and Key Management Personnel as at 30 June 2026 (31 December 2025: £nil).

Related Party Transactions: Inflexion Private Equity Partners LLP

Management Fees

For the period ended 30 June 2026, management fees charged from the Inflexion group of companies to the Group totalled £0.2m (HY 2025: £0.2m).

Balances Outstanding

On 22 June 2026, Washington Topco Limited declared a dividend of £20.0m. £12.0m (representing 60%) of the dividend was cash settled to GlobalData Plc prior to 30 June 2026, however £8.0m (representing 40%) payable to Inflexion Private Equity Partners LLP was outstanding as at 30 June 2026. There were no other balances outstanding in relation to the Inflexion group of companies as at 30 June 2026 (31 December 2025: £nil).

Related Party Transactions: Non-wholly owned subsidiaries

Washington Topco Limited and its subsidiaries are 60% owned, as such, the exemption to disclose transactions between group companies in accordance with IAS 24 does not apply. Transactions entered into with a member of the group of companies owned by Washington Topco Limited, and outstanding balances between the parties as at the period end are presented below.

Balances Outstanding

Related Party Transactions: Other Related Parties

Balances Outstanding

As at 31 December 2024, there was an outstanding loan note due to the pre-existing management of the Deallus group of companies amounting to £1.0m, generated as a result of the Deallus acquisition which completed on 31 December 2024. This was initially repayable on 30 June 2025 and accrued interest at a semi-annual compounded rate of 12%. The repayment date for the loan note was formally extended to 28 February 2026, and interest has continued to accrue on the same basis. In February 2026, £0.8m of the original principle was settled on the exit of a former member of the Deallus management. In June 2026, £0.1m was settled and redeemed in full by a different former member of the Deallus management. No further extension has been formally signed on the remaining outstanding balance; however, interest has continued to accrue on the same basis to 30 June 2026.

Following the Cambridge Healthcare Research Limited acquisition on 1 April 2026, a further £0.7m of loan notes were issued to the pre-existing management on the same terms as the loan notes already in issue.

As of 30 June 2026, the total liability in respect of loan notes in issue is £0.8m, being the principle plus accrued unpaid interest.

Acquisitions

Cambridge Healthcare Research Limited

On 1 April 2026, the Group acquired the entire share capital of Cambridge Healthcare Research Limited and its non-trading wholly owned subsidiary for cash consideration of £21.3m plus issuance of a loan note of £0.7m which has been classified as an amount owed to related parties within the Consolidated Statement of Financial Position. Cambridge Healthcare Research is a market-leading competitive intelligence (CI) solutions provider focused on the global life sciences sector. The acquisition creates the opportunity for the Group to build deeper, more embedded relationships with major brands within the pharmaceutical sector and creates the potential for GlobalData to deliver more value to our clients.

The goodwill recognised in relation to the acquisition is as follows:

Fair value

£m

In line with the provision of IFRS3, fair value adjustments may be made within the 12-month period from the date of acquisition which would result in an adjustment to the goodwill balance reported above. The goodwill that arose on the combination can be attributed to the assembled workforce, know-how and research methodology. The fair values of the identified intangible assets were calculated in line with the policies detailed within the Group's Annual Report and Accounts for the year ended 31 December 2025. The amount of goodwill which is expected to be deductible for tax purposes is £nil.

The Group incurred legal and professional expenses of £0.4m in relation to the acquisition, of which £0.2m were recognised in adjusting items in the Consolidated Income Statement in the period ended 30 June 2026, with the balance of £0.2m being recognised in adjusting items in the prior financial year. In the period from the date of acquisition to 30 June 2026, the trade of Cambridge Healthcare Research generated revenues of £4.2m and profit before tax of £0.1m. If the acquisition had occurred on 1 January 2026, Group revenue would have been £166.8m and Group profit before tax would have been £22.5m.

Cash Cost of Acquisitions

The cash cost of acquisitions comprises:

Subsequent events

As disclosed within note 11, during July 2026, the Group secured further financing headroom, upsizing its Non-Healthcare facility by £60.0m to £245.0m (on a new three-year term with 1 year extension option) as well as extending the £200.0m Healthcare facility by a further year to December 2028. As part of the amendments, within both facilities, the ACF element has been transferred into RCF facilities. The Group drew down £30.0m from the Non-Healthcare facility during July 2026.

On 13 August 2026, the Group completed a second Tender Offer, which resulted in the purchase and cancellation of shares with a total value of £30.0m.

Advisers

Company Secretary

Bob Hooper

Head Office and Registered Office

John Carpenter House

John Carpenter Street

London

EC4Y 0AN

Joint Broker

J.P. Morgan Cazenove

25 Bank Street

Canary Wharf

London

E14 5JP

Joint Broker

Panmure Gordon

One New Change

London

EC4M 9AF

Joint Broker

Numis Securities

45 Gresham Street

London

EC2V 7BF

Financial PR LLP

FTI Consulting

200 Aldersgate

Aldersgate Street

London

EC1A 4HD

Lawyers

Reed Smith

20 Primrose Street

London

EC2A 2RS

Auditor

Deloitte LLP

1 City Square

Leeds

LS1 2AL

Registrars

MUFG Corporate Markets

Central Square

29 Wellington Street

Leeds

LS1 4DL

Advisers (continued)

Bankers

NatWest Group

280 Bishopsgate

London

EC2M 4RB

Bankers

HSBC UK Bank Plc

1 Centenary Square

Birmingham

B1 1HQ

Registered number

Company No. 03925319